Proactive Investors - Run By Investors For Investors

Evgen Pharma looks to Spain for latest licensing deal

For a small and undisclosed upfront fee it is licensing the rights to 60 new chemical entities based on the core structure of sulforaphane, the active ingredient in the company's lead product SFX-01 for breast cancer.
Evgen Pharma looks to Spain for latest licensing deal
Evgen has 60 new chemical entities to add to the pipeline.

Evgen Pharma (LON:EVG) has struck an interesting deal with the Spanish National Research Council and the University of Seville.

For a small and undisclosed upfront fee it is licensing the rights to 60 new chemical entities based on the core structure of sulforaphane, the active ingredient in the company's lead product SFX-01 for breast cancer.

Evgen said it will use its Sulforadex platform to synthesise and stabilise the newly acquired compounds.

As well as the upfront payment, the firm’s new partners will receive cash as the drug or drugs hit certain milestones. They will also receive a royalty on any sales that won’t exceed 1%.

Chief executive Stephen Franklin said: “We are delighted to acquire the exclusive worldwide licensing rights to these novel compounds.

“The University of Seville has conducted an innovative medicinal chemistry programme based on sulforaphane and, like sulforaphane, these novel compounds have a requirement for our patented stabilisation technology.

“These new compounds give us the opportunity to lead the intellectual property space around sulforaphane and to build a drug development pipeline targeting several therapeutic markets within neurology and oncology."

View full EVG profile View Profile

Evgen Pharma Timeline

Newswire
December 12 2018
Article
October 21 2015

Related Articles

Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
A man's knee pain is highlighted with a red area that points to inflammation
January 23 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
Scientists in a lab
January 31 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use